PharmaVigilant has introduced I-Builder 2.0, an enhanced study-building solution that was designed to ease the study build process and technology transfer for sponsors.  I-Builder 2.0 provides the industry with a user interface for building EDC studies. I-Builder can support multiple users for building all phases of clinical research studies from simple studies to global, multicenter or adaptive study designs. 
  
 “The study design serves as the solid foundation for successful program execution.  Studies not based on the proper architecture suffer from cracks and data issues that result in costly delays,” said James DeSanti, Founder and Chief Executive Officer, PharmaVigilant.  “With I-Builder 2.0, PharmaVigilant is offering [a]...technology that makes it simple for sponsors to build innovative and adaptive study designs...using fewer internal resources.  And the new interface will ensure that sponsors can integrate I-Builder into their organizations with minimal training, and little need for any on-going support.” 
 
 I-Builder is a Web based, thin client application that can support multiple users for their global study design needs, and offers a study builder module enabling sponsors to build trials from simple to complex adaptive trials for Phase I-IV. 
  
 In addition to I-Builder 2.0, the company offers a full suite of clinical trial technology offerings including

Electronic Data Capture (EDC), data warehousing, Electronic Trial Master File System (eTMF), Remote Source Document Verification (rSDV), study administration and an

automated site payment system. PharmaVigilant focuses on Phase I-IV clinical trials, registries and other post-marketing studies.  The technology has supported more than 200,000 patients in 14 countries across North America, Europe, Asia, and Australia and continues to expand rapidly. 